Windlas Biotech Q4 FY26 results (Jan–Mar 2026) and concall

Healthcare · Concall AI · Call held 22 May 2026

Company page: Windlas Biotech share price, financials & guidance record

Windlas Biotech delivered a strong Q4 and FY26 performance, with robust revenue growth across all verticals, particularly CDMO and exports. The company achieved its highest post-listing EPS and maintained healthy profitability and liquidity. Management highlighted strategic investments in quality systems, capacity expansion (Plant 6), and a balanced capital allocation approach, including a buyback and proposed dividend, while addressing challenges in the trade generics segment.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q4 FY26: revenue up 17.2%, net profit up 0.0% against the same quarter last year.

₹ Cr · quarterly

Line item	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26
Revenue	175	187	195	203	210 +20%	222 +19%	233 +19%	238 +17%
Expenses	154	164	170	177	184	194	209	213
EBITDA	21	23	25	26	27 +29%	29 +26%	24 −4%	25 −4%
Margin	12%	12%	13%	13%	13%	13%	10%	11%
Other income	4	5	4	5	5	4	5	4
Interest	0	1	1	1	1	1	1	1
Depreciation	6	6	7	8	7	8	8	8
Profit before tax	18	20	20	21	23 +28%	24 +20%	20 +0%	20 −5%
Tax rate	26%	23%	23%	22%	24%	25%	25%	21%
Net profit	13	16	16	16	18 +38%	18 +13%	15 −6%	16 +0%
EPS	6.45	7.49	7.45	7.77	8.43	8.45	7.12	7.58

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls